Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
10 2020
Historique:
received: 14 12 2019
revised: 03 06 2020
accepted: 12 06 2020
entrez: 24 9 2020
pubmed: 25 9 2020
medline: 21 10 2020
Statut: ppublish

Résumé

Mental disorders can adversely affect HIV treatment outcomes and survival. Data are scarce on premature deaths in people with mental disorders in HIV-positive populations, particularly in low-income and middle-income countries. In this study, we quantified excess mortality associated with mental disorders in HIV-positive people in South Africa, adjusting for HIV treatment outcomes. For this cohort study, we analysed routinely collected data on HIV-positive adults receiving antiretroviral therapy (ART) in Cape Town, South Africa between Jan 1, 2004, to Dec 31, 2017. Data from three ART programmes were linked with routine medical records on mental health treatment from Jan 1, 2010, to Dec 31, 2017, and mortality surveillance data from the South African National Population Register up to Dec 31, 2017. People living with HIV aged 15 years or older who initiated ART at a programme site were eligible for analysis. We followed up patients from ART initiation or Jan 1, 2010, whichever occurred later, to transfer, death, or Dec 31, 2017. Patients were considered as having a history of mental illness if they had ever received psychiatric medication or been hospitalised for a mental disorder. We calculated adjusted hazard ratios (aHRs) with 95% CIs for associations between history of mental illness, mortality, and HIV treatment outcomes (retention in care with viral load suppression [VLS; viral load <1000 copies per mL], retention in care with non-suppressed viral load [NVL; viral load ≥1000 copies per mL], and loss to follow-up [LTFU; >180 days late for a clinic visit at closure of the database]) using Cox proportional hazard regression and multistate models. 58 664 patients were followed up for a median of 4·3 years (IQR 2·1-6·4), 2927 (5·0%) of whom had a history of mental illness. After adjustment for age, sex, treatment programme, and year of ART initiation, history of mental illness was associated with increased risk of mortality from all causes (aHR 2·98 [95% CI 2·69-3·30]), natural causes (3·00 [2·69-3·36]), and unnatural causes (2·10 [1·27-3·49]), compared with no history of mental illness. Risk of all-cause mortality in people with a history of mental illness remained increased in multivariable analysis adjusted for age, sex, treatment programme, year of ART initiation, CD4 count and WHO clinical stage at ART initiation, retention in HIV care with or without VLS, and LTFU (2·73 [2·46-3·02]). In our multistate model, adjusted for age, sex, year of ART initiation, cumulative time with NVL, and WHO clinical stage and CD4 cell count at ART initiation, rates of excess all-cause mortality in people with history of mental illness were greatest in patients retained in care with VLS (aHR 3·43 [95% CI 2·83-4·15]), followed by patients retained in care with NVL (2·74 [2·32-3·24]), and smallest in those LTFU (2·12 [1·78-2·53]). History of mental illness was also associated with increased risk of HIV viral rebound (transitioning from VLS to NVL; 1·50 [1·32-1·69]) and LTFU in people with VLS (1·19 [1·06-1·34]). Mental illness was associated with substantial excess mortality in HIV-positive adults in Cape Town. Excess mortality among people with a history of mental illness occurred independently of HIV treatment success. Interventions to reduce excess mortality should address the complex physical and mental health-care needs of people living with HIV and mental illness. National Institutes of Health, Swiss National Science Foundation, South African Medical Research Council.

Sections du résumé

BACKGROUND
Mental disorders can adversely affect HIV treatment outcomes and survival. Data are scarce on premature deaths in people with mental disorders in HIV-positive populations, particularly in low-income and middle-income countries. In this study, we quantified excess mortality associated with mental disorders in HIV-positive people in South Africa, adjusting for HIV treatment outcomes.
METHODS
For this cohort study, we analysed routinely collected data on HIV-positive adults receiving antiretroviral therapy (ART) in Cape Town, South Africa between Jan 1, 2004, to Dec 31, 2017. Data from three ART programmes were linked with routine medical records on mental health treatment from Jan 1, 2010, to Dec 31, 2017, and mortality surveillance data from the South African National Population Register up to Dec 31, 2017. People living with HIV aged 15 years or older who initiated ART at a programme site were eligible for analysis. We followed up patients from ART initiation or Jan 1, 2010, whichever occurred later, to transfer, death, or Dec 31, 2017. Patients were considered as having a history of mental illness if they had ever received psychiatric medication or been hospitalised for a mental disorder. We calculated adjusted hazard ratios (aHRs) with 95% CIs for associations between history of mental illness, mortality, and HIV treatment outcomes (retention in care with viral load suppression [VLS; viral load <1000 copies per mL], retention in care with non-suppressed viral load [NVL; viral load ≥1000 copies per mL], and loss to follow-up [LTFU; >180 days late for a clinic visit at closure of the database]) using Cox proportional hazard regression and multistate models.
RESULTS
58 664 patients were followed up for a median of 4·3 years (IQR 2·1-6·4), 2927 (5·0%) of whom had a history of mental illness. After adjustment for age, sex, treatment programme, and year of ART initiation, history of mental illness was associated with increased risk of mortality from all causes (aHR 2·98 [95% CI 2·69-3·30]), natural causes (3·00 [2·69-3·36]), and unnatural causes (2·10 [1·27-3·49]), compared with no history of mental illness. Risk of all-cause mortality in people with a history of mental illness remained increased in multivariable analysis adjusted for age, sex, treatment programme, year of ART initiation, CD4 count and WHO clinical stage at ART initiation, retention in HIV care with or without VLS, and LTFU (2·73 [2·46-3·02]). In our multistate model, adjusted for age, sex, year of ART initiation, cumulative time with NVL, and WHO clinical stage and CD4 cell count at ART initiation, rates of excess all-cause mortality in people with history of mental illness were greatest in patients retained in care with VLS (aHR 3·43 [95% CI 2·83-4·15]), followed by patients retained in care with NVL (2·74 [2·32-3·24]), and smallest in those LTFU (2·12 [1·78-2·53]). History of mental illness was also associated with increased risk of HIV viral rebound (transitioning from VLS to NVL; 1·50 [1·32-1·69]) and LTFU in people with VLS (1·19 [1·06-1·34]).
INTERPRETATION
Mental illness was associated with substantial excess mortality in HIV-positive adults in Cape Town. Excess mortality among people with a history of mental illness occurred independently of HIV treatment success. Interventions to reduce excess mortality should address the complex physical and mental health-care needs of people living with HIV and mental illness.
FUNDING
National Institutes of Health, Swiss National Science Foundation, South African Medical Research Council.

Identifiants

pubmed: 32971055
pii: S2214-109X(20)30279-5
doi: 10.1016/S2214-109X(20)30279-5
pmc: PMC7582785
mid: NIHMS1633386
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1326-e1334

Subventions

Organisme : NIMH NIH HHS
ID : K01 MH120258
Pays : United States
Organisme : NIMH NIH HHS
ID : T32 MH096724
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Organisme : NIMH NIH HHS
ID : U19 MH113203
Pays : United States

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
Br J Psychiatry. 2016 Mar;208(3):223-31
pubmed: 26932485
Epidemiology. 2009 Jul;20(4):488-95
pubmed: 19525685
Pilot Feasibility Stud. 2018 Jan 24;4:36
pubmed: 29403650
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
Stat Med. 2017 Dec 20;36(29):4719-4742
pubmed: 28872690
Comput Methods Programs Biomed. 2010 Sep;99(3):261-74
pubmed: 20227129
S Afr Med J. 2009 May;99(5 Pt 2):339-44
pubmed: 19588796
Circulation. 2008 Oct 21;118(17):1768-75
pubmed: 18824640
J Clin Psychiatry. 2013 Jan;74(1):31-7
pubmed: 23419223
World Psychiatry. 2017 Feb;16(1):30-40
pubmed: 28127922
Lancet. 2018 Oct 27;392(10157):1553-1598
pubmed: 30314863
Lancet HIV. 2015 Aug;2(8):e344-50
pubmed: 26423377
JAMA. 2001 Mar 21;285(11):1466-74
pubmed: 11255423
AIDS. 2017 Jan 14;31(2):263-271
pubmed: 27835614
Am J Public Health. 2004 Jul;94(7):1133-40
pubmed: 15226133
Front Psychiatry. 2018 Sep 28;9:463
pubmed: 30323773
BMJ Open. 2020 May 15;10(5):e035246
pubmed: 32414825
Br J Psychiatry. 2013 Sep;203(3):297-302
pubmed: 23969485
Int J Popul Data Sci. 2019 Nov 20;4(2):1143
pubmed: 32935043
AIDS Patient Care STDS. 2008 Feb;22(2):147-58
pubmed: 18260806
World Psychiatry. 2011 Jun;10(2):138-51
pubmed: 21633691
J Affect Disord. 2019 Dec 1;259:302-313
pubmed: 31450139
J Int AIDS Soc. 2018 Feb;21(2):
pubmed: 29479867
South Afr J HIV Med. 2017 Jul 15;18(1):776
pubmed: 29568644
Int Rev Psychiatry. 2007 Apr;19(2):113-22
pubmed: 17464789
Br J Psychiatry. 2006 Sep;189:241-6
pubmed: 16946359
BMC Psychiatry. 2011 Oct 10;11:165
pubmed: 21985179
Curr HIV/AIDS Rep. 2014 Sep;11(3):291-307
pubmed: 25038748

Auteurs

Andreas D Haas (AD)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Electronic address: andreas.haas@ispm.unibe.ch.

Yann Ruffieux (Y)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Leigh Luella van den Heuvel (LL)

Department of Psychiatry, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South Africa.

Crick Lund (C)

Alan J Flisher Centre for Public Mental Health, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa; King's Global Health Institute, Centre for Global Mental Health, Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Andrew Boulle (A)

Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; Western Cape Provincial Department of Health, Cape Town, South Africa.

Jonathan Euvrard (J)

Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.

Catherine Orrell (C)

Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Hans W Prozesky (HW)

Division of Infectious Diseases, Department of Medicine, Tygerberg Academic Hospital, University of Stellenbosch, Cape Town, South Africa.

Nicki Tiffin (N)

Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; Wellcome Centre for Infectious Disease Research in Africa, University of Cape Town, Cape Town, South Africa; Division of Computational Biology, University of Cape Town, Cape Town, South Africa.

Kathryn L Lovero (KL)

Department of Psychiatry and New York State Psychiatric Institute, Columbia University, New York, NY, USA.

Mpho Tlali (M)

Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.

Mary-Ann Davies (MA)

Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.

Milton L Wainberg (ML)

Department of Psychiatry and New York State Psychiatric Institute, Columbia University, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH